Medical/Pharmaceuticals

Everest Medicines Announces Interim Results for First Half of 2025

SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 a...

2025-08-29 07:52 2780

Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs

TOKYO, Aug. 28, 2025 /PRNewswire/ -- Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hema...

2025-08-28 22:00 1207

D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers

* Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have had prior treatment with platinum-based chemotherapy and anti-PD-(L)1 antibody but have not been previously treate...

2025-08-28 21:00 3293

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...

2025-08-28 20:00 2521

Hua Medicine Announces 2025 Interim Results

* Sales of HuaTangNing (华堂宁®) increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achie...

2025-08-28 17:58 2728

Futurise Lead RegTalk 2025: AI Medical Devices in Malaysia - Balancing Innovation and Safety

CYBERJAYA, Malaysia, Aug. 28, 2025 /PRNewswire/ -- Futurise Sdn Bhd (Futurise), in collaboration with the Medical Device Authority (MDA), hosted the latest edition of RegTalk at the Siemens Healthineers Experience Center, focusing on "AI Medical Devices inMalaysia – Balancing Innovation & Safety....

2025-08-28 15:01 2918

Top Thermal Camera Manufacturer Raytron Makes Breakthroughs in Scientific Research

YANTAI, China, Aug. 28, 2025 /PRNewswire/ -- As research in AI, advanced materials, renewable energy, and climate research accelerates, scientists require highly sensitive, precise, stable, and cost-effective tools to explore the invisible. Infrared thermal imaging has emerged as a vital "invisib...

2025-08-28 14:00 1448

FIRST CLINICAL EVIDENCE PUBLISHED ON AROA's ENIVO™ SYSTEM FOR SURGICAL DEAD SPACE MANAGEMENT.

AUCKLAND, New Zealand, Aug. 27, 2025 /PRNewswire/ -- AROA is pleased to announce the findings of the first in human study involving its new ENIVO platform technology. The study is the subject of a peer-reviewed publication entitledProspective, First-in-Human Clinical Evaluation of a Novel Tissue ...

2025-08-28 12:29 1369

ACROBiosystems and DAAN Biotherapeutics Sign Strategic MOU for the Development of Precision Immuno-Oncology Therapeutics

SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ -- ACROBiosystems, a global biotechnology company dedicated to accelerating the drug development process through innovative tools and solutions, announced that it has entered into a strategic Memorandum of Understanding (MOU) with DAAN Biotherapeutic...

2025-08-28 09:54 1634

AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector

HONG KONG, Aug. 28, 2025 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are ...

2025-08-28 07:45 1565

Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study

-          ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. -          Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron...

2025-08-28 07:45 1274

Bestqool Honors Workers With Light-Based Recovery Solutions This Labor Day

From Aug 27 through Sep 4, all Bestqool Products will be available at unbeatab le prices. NEW YORK, Aug. 27, 2025 /PRNewswire/ -- After long hours of daily work, the body needs more than rest — it requires a sustainable, gentle, and easy-to-maintain recovery method. Bestqool, a health and wellnes...

2025-08-27 23:31 1653

Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand

HONG KONG, Aug. 27, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across...

2025-08-27 23:09 2366

Harbour BioMed Reports 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its i...

2025-08-27 22:40 2138

XtalPi Holdings Announces 2025 Interim Results

SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...

2025-08-27 22:26 2778

XtalPi Holdings Announces 2025 Interim Results

SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...

2025-08-27 22:23 2611

Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

Start Your Journey to Access Vast Chemical Space CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hi...

2025-08-27 21:30 1544

Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA Approval

SHENYANG, China, Aug. 27, 2025 /PRNewswire/ -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval fromChina's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved inChina, and the world's first w...

2025-08-27 21:03 1722

NUHS SPEARHEADS AI-POWERED BRAIN CARE PROGRAMME TO TACKLE UNDERDIAGNOSIS AND IMPROVE PREVENTION OF DEMENTIA

Novel initiative in Asia integrates predictive AI with personalised health coaching to empower early action and prevention SINGAPORE, Aug. 27, 2025 /PRNewswire/ -- Dementia remains a hidden epidemic in Singapore, with slightly more than half of all cases going undiagnosed. According to the Well-b...

2025-08-27 21:00 1897

Fosun International: Total Revenue for the First Half of 2025 Reaches RMB87.28 Billion, Industrial Operation Profit Amounts to RMB3.15 Billion

HONG KONG, Aug. 27, 2025 /PRNewswire/ -- On 27 August, Fosun International Limited (HKEX stock code: 00656) announced its interim results for the six months ended30 June 2025. In the first half of 2025, Fosun actively captured macroeconomic trends, maintained a clear strategic focus, and leverag...

2025-08-27 20:40 3523
1 ... 52535455565758 ... 646

Week's Top Stories